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A clinical study of zopiclone was performed using doses of
5 and 10 mg. Samples of oral fluid were collected using the
Statsure and Intercept devices, and blood samples were collected
simultaneously. Concentrations of zopiclone in samples of oral
fluid and blood were determined with liquid chromatography–
mass spectrometry, and concentrations in undiluted oral fluid
were calculated. The concentrations of zopiclone in oral fluid
were generally higher when using the Intercept compared to the
Statsure device; the median oral fluid/whole blood concentration
ratios were 3.8 (range 1.5–15.9) and 1.9 (range 1.2–4.6),
respectively (n = 21). The correlation between zopiclone
concentrations in oral fluid collected with the two devices was
fairly poor, r2 = 0.35. The results indicate that the type of sampling
device may significantly affect the analytical result for zopiclone in
sampled oral fluid.
Introduction
Zopiclone is the most frequently prescribed hypnotic drug in
Norway. In 2008, 6.4% of the population had one or more pre-
scriptions of zopiclone dispensed from a pharmacy with an
average of 171 defined daily doses dispensed per patient (1).
Zopiclone was also the most frequently found drug in a Nor-
wegian roadside survey of drugs and driving performed in
2005–2006 (2); 1.0% of 10,816 drivers had zopiclone concen-
trations above 25 ng/mL in oral fluid. The Intercept oral fluid
collection device was used in that study. A similar roadside
survey was performed in 2008–2009; this study was a part of
the European DRUID project (3). In this study, the Statsure col-
lection device was used. Zopiclone was also the most frequently
drug detected; however, 0.7% of 9391 drivers had concentra-
tions above 25 ng/mL in oral fluid, which is significantly lower
than in the previous study (p < 0.02).
Drug concentrations in collected oral fluid may be affected
by the sampling process and by the fluid collection device in it-
self (4–6). The oral fluid collection pad used in the Intercept de-
vice is made of cotton treated with a solution containing
sodium chloride, citric acid, sodium benzoate, potassium sor-
bate, gelatine, and sodium hydroxide, according to the package
insert. Some of these compounds stimulate the production of
saliva and may also affect the local pH and may therefore affect
the concentration of zopiclone in the sampled oral fluid. The
oral fluid collection pad used in the Statsure device is made
with cellulose and is not treated with any chemicals to stimu-
late the production of saliva (6). These differences between
the sampling devices might affect the zopiclone concentra-
tion in collected oral fluid samples. In addition, the measured
concentrations in oral fluid also depend on the recovery of
zopiclone from the sampling device.
On this background we decided to compare the zopiclone
concentrations in oral fluid collected with the two devices to
see whether the use of different collection devices could explain
the differences in median zopiclone concentrations observed in
the two roadside surveys of drugs and driving.
Materials and Methods
Chemicals and reagents
High-performance liquid chromatography (HPLC)-grade
acetonitrile was obtained from Lab-Scan (Poch S.A., Gliwice,
Poland), ammonium acetate from Merck (Darmstadt, Ger-
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many), zopiclone from European Directorate for the Quality of
Medicines and Healthcare (European Pharmacopoeia, Stras-
bourg, France), and 7-aminoflunitrazepam-d7 and diazepam-
d5 from Cerilliant (Round Rock, TX).
Analytical testing
Samples of oral fluid were weighed to determine the amount
collected. As the specific gravity of oral fluid is 1.002–1.006
g/mL (7,8), the weight in grams is a close approximation of the
volume in milliliters. The concentrations of zopiclone in sam-
ples of preserved oral fluid were analyzed by HPLC and tandem
mass spectrometry (MS) after extracting with ethylacetate/hep-
tane (4:1) (9). Five calibration standards ranging from 0.4 to
150 ng/mL in preserved oral fluid were used. The oral fluid was
diluted by a factor of 3 for the Intercept device and 2 for the
Statsure device. 7-Aminoflunitrazepam-d7 was used as internal
standard. Quality control (QC) samples were prepared at con-
centrations 0.8, 27, and 78 ng/mL.
The Intercept device contains 0.8 mL buffer and the Statsure
device 1.0 mL. The collected oral fluid was therefore diluted
with these buffer volumes after sampling. Drug concentra-
tions in undiluted oral fluid (CUOF) were calculated as follows:
CUOF = COFB × (VBuffer+VOF)/VOF, where COFB = drug concen-
tration in oral fluid-buffer mixture, VBuffer = volume of buffer,
and VOF = volume of oral fluid.
Concentrations of zopiclone in full blood were determined by
HPLC–MS using a Waters ZQ MS with a 2695 Alliance pump
(Waters, Milford, MA). Six zopiclone calibration standards with
concentrations ranging from 10 to 583 ng/mL were used. QC
samples were prepared at 27 and 389 ng/mL.
Calibrators and QC samples were prepared in advance in
acetonitrile solutions in glass vials stored in a freezer at –20°C.
After reaching room temperature, 50 µL from each solution
was transferred to plastic tubes, followed by 50 µL water before
400 µL whole blood from the national blood bank services was
added.
Calibrators, QC samples, and samples were all added to 50 µL
of the internal standard diazepam-d5 (2900 ng/mL) and then
vortex mixed. Keeping the samples cold with an ice bath, 500
µL cold acetonitrile (approximately 4°C) was added, and each
individual tube was immediately vortex mixed. Finally all the
samples were shaken vigorously on a multitube vortexer for 60
s, put in a freezer at about –20°C for at least 10 min and then
centrifuged for 10 min at 6000 × g at 4°C. The supernatant was
transferred to plastic autosampler vials while keeping the sam-
ples cold and analyzed by LC–MS.
Separation was performed with a Waters Symmetry C18-
column or X-terra MS-column (2.1 × 150 mm, 3.5 μm), with
gradient elution at a flow rate of 0.3 mL/min. The mobile
phase consisted of acetonitrile and 5 mM ammonium acetate
buffer at pH 5 using a gradient from 30% to 80% acetonitrile
in 8 min followed by a wash step. The pre-column volume was
set to 0.95 mL. The overall cycle time was 15 min. The column
temperature was held at 35°C, and the injection volume was
10 µL.
The samples were analyzed by LC–MS using positive ioniza-
tion in the selected ion monitoring (SIM) mode. The capillary
voltage was set to 3.0 kV, the source block temperature was
120°C, and the desolvation gas (nitrogen) was heated to 300°C
and delivered at a flow rate of 500 L/h. The cone gas (nitrogen)
was set to 70 L/h. System operation and data acquisition were
controlled using Mass Lynx 4.1 software. Data were processed
with the QuanLynx program.
The molecular ion of zopiclone (m/z 389.1) and the internal
standard diazepam-d5 (m/z 285.1) and one fragment ion of
both zopiclone (m/z 245.1) and the internal standard (m/z
198.1) were recorded. Analytes were identified by comparing
the retention time and ion ratio with those of the calibrators
and QC samples. Based on peak heights, the response of the
molecular ion of zopiclone relative to that of the internal stan-
dard was used for quantitation. A weighted (1/x) second-order
regression line, excluding the origin, was applied to the cali-
bration standards.
Clinical study
Sixteen healthy volunteers participated in a study of zopi-
clone; five of them participated two days with two different
doses of zopiclone. The study was primarily designed as a
double-blinded crossover study to investigate pharmacoki-
netics and psychomotor abilities, and a large number of sam-
ples of blood and oral fluid were taken for those purposes (re-
sults will be published separately). The time points for
additional sampling of oral fluid for comparison of collection
devices, and which participants to include, were decided based
on practical reasons to avoid interfering with the primary
study.
Doses of 5 or 10 mg zopiclone were given to 6 and 15 par-
ticipants, respectively, at about 9 a.m., and blood and oral fluid
samples were taken at specified time points after drug admin-
istration. The earliest sampling was performed about 1 h after
administration, and the latest one about 10 h after adminis-
tration. Breakfast and dinner were served about 2½–3 h and 8
h after administration of zopiclone, respectively, and oral fluid
samples were collected at least 2 h after intake of food.
Collection of oral fluid and blood
The Statsure Saliva Sampler (Saliva Diagnostic Systems,
Framingham, MA) was used to collect a sample of oral fluid
shortly before using the Intercept Oral Specimen Collection
Device (OraSure Technologies, Bethlehem, PA). This sampling
sequence was used in all cases because the Intercept device
contains chemicals that stimulate the production of oral fluid,
and the Statsure device does not. In addition, samples of oral
fluid were collected using the Intercept device 1–3 h before
using the Statsure device.
Samples of whole blood were collected using 5-mL Vacu-
tainer® tubes containing 20 mg sodium fluoride and 143 I.U.
sodium heparin (BD Vacutainer Systems, Belliver Industrial
Estate, Plymouth, U.K.). Blood sampling was performed
simultaneously with the collection of the oral fluid samples.
Oral fluid and blood samples were stored in a refrigerator at
about 5°C for up to 24 h after sampling, and then either ana-
lyzed or frozen at about –20°C for later analysis.
Statistical tests
Pearson’s Chi-Square test was used for comparing preva-
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lences. The two-sided Wilcoxon Signed-Rank test was used for
comparing paired OF/B ratios for different collection devices.
Results and Discussion
Method validation
Some validation of the analytical method for oral fluid has
been published previously for a number of drugs (9), and some
additional data for zopiclone are presented here. The limit of
detection (LOD, defined as a peak height corresponding to the
mean of negative specimens plus 3 times the standard devia-
tion) was 0.1 ng/mL, the lower limit of quantitation (LLOQ, de-
fined as defined as a peak height corresponding to the mean of
negative specimens plus 10 times the standard deviation) was
0.3 ng/mL. The upper limit of quantitation (ULOQ) was 150
ng/mL, determined by inspection of calibration curves. The in-
terassay precision and accuracy expressed as bias was 16 to
19% and –2 to –6% respectively (n = 26). Recoveries for the
liquid–liquid extraction of zopiclone from the oral fluid/buffer
mixtures were 60% for the Statsure buffer and 65% for the In-
tercept buffer. Matrix effects evaluated by the method pro-
posed by Matuszewski et al. (10) were 165% for Statsure and
88% for Intercept when compared to neat mobile phase, and
114% and 80% when compared to extracted buffer. Relative
matrix effects expressed as the coefficient of variation were
5% for Statsure and 23% for Intercept. The recoveries from the
sampling devices were 74% for Statsure and 80% for Intercept
devices.
For the analysis of zopiclone in blood, the interassay preci-
sions for low and high QC samples were 12% and 5% (n = 14),
respectively, and the accuracy expressed as bias was 1.2% and
–7%. LOD and LLOQ were determined by analysing 7 different
zopiclone negative whole blood specimens. A total of 11 series
were analyzed, differing either in day of analysis or analyst. The
LOD and LLOQ were 3 ng/mL and 7 ng/mL, respectivey. The
ULOQ was 1170 ng/mL.
To evaluate recovery and matrix effects, samples from six dif-
ferent lots of human whole blood were used. Three sets of
samples were prepared. Set A consisted of extracts of the six
blank matrixes spiked before extraction, set B of extracts of the
six different blank matrixes spiked after extraction with the
same amount of standards as used for set A, and set C consisted
of neat standard solutions. The extraction recovery (RE) was
determined by measuring an extracted sample against a post-
extraction spiked sample: RE = (A/B) × 100%, where A is the
peak height for the extracted samples and B the peak height for
post-extracted samples. The matrix effect (M) was calculated by
referring the peak height of the samples spiked after extraction
(B) with the height found for the neat standards (C): M = (B/C)
× 100%, where B is the peak height for the post-extracted
samples and C is the peak height for the neat standards.
Set A was prepared by mixing 50 µL of a zopiclone solution
in acetonitrile (two concentration levels) with 50 µL water
and 400 µL whole blood, whereas set B was prepared by mixing
50 µL acetonitrile, 50 µL water, and 400 µL whole blood. After
the protein precipitation procedure 200 µL of each extracted
sample was transferred to glass tubes. 20 µL of zopiclone so-
lution was added to set B, and the extracts from both set A and
B were evaporated to dryness under N2 at 40°C using a Zymark
Turbovap (Sotax AG, Basel, Switzerland). The residue was then
dissolved in 180 µL acetonitrile/water (50:50, v/v), and 20 µL
acetonitrile was added. To prepare the neat standards, 20 µL
zopiclone solution in acetonitrile was added to 180 µL of the re-
constitution solution.
Recovery and matrix effects were calculated at two concen-
tration levels and found to be 76% and 128% at 29 ng/mL and
81% and 112% at 389 ng/mL, respectively. The relative matrix
effect as given by the relative coefficient of variation was 15%
at the low concentration level and 7% at the high level.
Comparison of zopiclone concentrations in samples of
oral fluid and blood
A total of 21 parallel samples of oral fluid using Statsure and
Intercept devices were obtained combined with simultaneously
taken blood samples. The analytical results are presented in
Figure 1. The results indicated a significant difference in OF/B
ratios for zopiclone using the two sampling devices (p = 0.001).
The mean and median OF/B ratios for the Intercept device were
4.7 and 3.8, respectively, whereas the mean and median OF/B
ratios for the Statsure device were 2.3 and 1.9. Wide variations
Figure 1. Concentrations of zopiclone in oral fluid (un-diluted) collected
with Intercept (●) and Statsure (∆) sampling devices in relation to zopiclone
concentrations in blood.
Figure 2. Concentrations of zopiclone in oral fluid (un-diluted) collected
with the Statsure sampling device compared to the Intercept device.
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of OF/B ratios were obtained; the ranges were 1.5–15.9 for In-
tercept and 1.2–4.6 for Statsure. The OF/B ratios seemed not to
be normally distributed, and the “apparent” relative standard de-
viations were 46% and 75% for the Statsure and Intercept de-
vices, respectively.
Paired samples (from the same subjects) taken with the In-
tercept device 1–3 h before using the Statsure device showed a
mean and median OF/B ratio of 5.5 and 3.8 (n = 21), respec-
tively, indicating that taking an oral fluid sample with the Stat-
sure device shortly before using the Intercept device did not sig-
nificantly affect the Intercept OF/B ratios (p = 0.86).
The zopiclone concentration ratio between oral fluid and
plasma has previously been found to be 2.3; however, the
method for sampling oral fluid was not described (11). Using a
plasma/blood ratio of 1.0 (12), the concentration ratio between
oral fluid and blood (OF/B ratio) would also be 2.3; this is sim-
ilar to the mean OF/B ratio we observed for the Statsure device.
In a recent study using the Intercept device, the mean OF/B
ratio for zopiclone in four subjects was 3.7 (13), which is lower
than the mean OF/B ratio we observed in this study. However,
the median values were similar.
The concentrations of zopiclone in undiluted oral fluid are
presented in Figure 2. The correlation between drug concen-
trations using those two sampling kits was fairly poor (r2 =
0.35).
The results of this study indicate that the two sampling de-
vices for oral fluid produced quite different analytical results for
zopiclone. The differences in the two sampling devices may ex-
plain the observed differences in zopiclone concentrations in
the two Norwegian roadside surveys of drugs and driving. The
Intercept sampling pad contains saliva-stimulating agents that
also affect the local pH of oral fluid in the mouth, and it may
therefore also affect the equilibrium for zopiclone between
blood and oral fluid. This may, at least in part, explain differ-
ences in OF/B ratios for the two devices. Studies of the re-
covery of zopiclone from the two collection devices did not re-
veal any marked differences (results not shown).
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